SBC Medical Group Holdings Incorporated SBC R2K
Company Overview
SBC Medical Group Holdings Incorporated, together with its subsidiaries, provides management services to cosmetic treatment centers in Japan, Vietnam, the United States, and Singapore. The company offers advertising and marketing services across social media networks; staff management services, such as recruitment and training; booking reservations for franchisee clinic customers; assistance with franchisee employee housing rentals; leasehold improvement services; and design services for clinics, medical equipment, and medical consumables procurement. It also provides loyalty program management, labor and function supporting, and management consulting services; and IT software solutions, as well as engages in franchising activities; and distributes medical equipment and devices, implants, injection materials, other medical consumables, skin care and beauty products, and cosmetic products to franchisee clinics for resale to clinic customers. In addition, the company offers surgical and non-surgical surgeries that include breast augmentation; liposuction; rejuvenation treatments, such as treatment of wrinkles, acne, scars, cellulite, excess fat, discoloration, and signs of aging; laser skin toning and spot removal; eyes double fold surgery; rhinoplasty; treatment of osmidrosis and hyperhidrosis; hair transplants; gynecological formation treatments; laser hair removal; face line surgeries; cosmetical dental procedures; tattoo removal; lasik eye surgery; lateral canthoplasty; brow lift procedures; androgenetic alopecia treatment; and cheek sagging prevention methods. Further, it owns and operates treatment centers under the SBC brand. SBC Medical Group Holdings Incorporated was founded in 2000 and is headquartered in Irvine, California.
Why Investors Should Care
Generates a return on equity of 16.5%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 21.1%.
Net profit has compounded at 13.8% per year over the last five years.
Trades at a P/E of 10.3, below the sector median of 27.4.
Maintains a net profit margin of 24.1%.
Carries low leverage with a debt-to-equity ratio of 0.19.
Recent Developments
- Dec 2025 Revenue of $173.61M (-15.5% YoY); net profit $50.99M.
- Trailing 12 Months Year-on-year growth — revenue -9.0%, earnings -47.1%.
- 5-Year Trend Long-term compounding — revenue CAGR -5.3%, profit CAGR 13.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -5.29% |
| 1 Year: | -9.00% |
Compounded Profit Growth
| 5 Years: | 13.80% |
| 1 Year: | -47.10% |
Stock Price Performance
| 1 Year: | -4.52% |
| 6 Months: | +10.75% |
| 3 Months: | +36.88% |
| 1 Month: | +38.72% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)63.26 · Neutral
P/E of 10.30 is below the sector median of 27.38 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 21.1%.
- Excellent profit margin of 24.1%.
- Profit CAGR of 13.8% over 5 years.
- Generates positive free cash flow.
CONS
- Revenue declined at -5.3% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Industrials).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SBC SBC Medical Group Holdings Incorporated R2K | 4.12 | 10.30 | $423.73M | 0.00% | 21.13% | 16.46% | -5.29% | 13.80% |
| 2 | SPCX Space Exploration Technologies Corp. R3KAIDEFENCE | 147.95 | -134.50 | $1.12T | 0.00% | -3.22% | -11.95% | 34.08% | -3.34% |
| 3 | CAT Caterpillar Inc. SPXR3K | 813.94 | 35.05 | $374.15B | 0.76% | 17.98% | 56.97% | 2.29% | 5.24% |
| 4 | GE GE Aerospace SPXR3KDEFENCE | 337.12 | 39.85 | $349.78B | 0.50% | 9.52% | 48.23% | -7.42% | -5.36% |
| 5 | RTX RTX Corporation SPXR3KDEFENCE | 200.79 | 35.41 | $270.62B | 1.31% | 8.28% | 12.27% | 2.61% | 2.62% |
| 6 | GEV GE Vernova Inc. SPXR3KAI | 941.95 | 26.98 | $250.87B | 0.20% | 6.30% | 82.58% | 8.68% | - |
| 7 | DE Deere & Company SPXR3K | 693.53 | 39.29 | $187.33B | 1.05% | 12.53% | 18.35% | 3.43% | 5.10% |
| 8 | UNP Union Pacific Corporation SPXR3K | 291.88 | 23.83 | $173.40B | 1.92% | 15.22% | 39.70% | 2.30% | 7.77% |
| 9 | BA The Boeing Company SPXR3KDEFENCE | 212.25 | 76.08 | $167.63B | 0.00% | -9.01% | - | 1.67% | -3.28% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 47.28M | 54.81M | 53.10M | 53.08M | 47.33M | 43.36M | 43.35M | 43.06M |
| Gross Profit | - | - | - | - | 33.50M | 39.52M | 39.42M | 43.24M | 37.73M | 30.01M | 30.61M | 30.35M |
| Operating Income | -1.28K | -303.62K | -388.45K | -473.37K | 20.02M | 24.46M | 27.29M | 13.83M | 24.20M | 14.55M | 15.88M | 17.72M |
| Net Income | -1.28K | -11.42K | 613.33K | 196.79K | 8.36M | 18.76M | 18.48M | 2.83M | 21.50M | 2.46M | 12.82M | 11.31M |
| Diluted EPS | - | - | - | - | 0.09 | 0.20 | 0.20 | 0.03 | 0.21 | 0.02 | 0.12 | 0.11 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 193.54M | 205.42M | 173.61M |
| Gross Profit | 137.30M | 156.05M | 127.28M |
| Operating Income | 70.66M | 70.30M | 67.49M |
| Net Income | 39.37M | 46.61M | 50.99M |
| Diluted EPS | 0.42 | 0.48 | 0.50 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 119.94M | 258.81M | 266.08M | 380.45M |
| Total Equity | -3.36M | 142.16M | 195.11M | 248.28M |
| Cash & Equivalents | 485.56K | 103.02M | 125.04M | 163.77M |
| Long Term Debt | - | - | 6.60M | 42.83M |
| Total Liabilities | 4.59M | 115.00M | 71.06M | 117.14M |
| Current Liabilities | 566.01K | 92.45M | 61.19M | 61.12M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | 50.67M | 20.58M | 24.67M |
| Investing Cash Flow | 1.79M | -10.10M | -20.97M |
| Financing Cash Flow | 6.14M | 22.97M | 38.29M |
| Capital Expenditure | -8.54M | -2.56M | -1.40M |
| Free Cash Flow | 42.13M | 18.02M | 23.27M |
| Share Buybacks | - | 0 | 5.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 70.9% | 76.0% | 73.3% |
| Operating Margin % | 36.5% | 34.2% | 38.9% |
| Net Margin % | 20.3% | 22.7% | 29.4% |
| ROE % | 27.7% | 23.9% | 20.5% |
| ROCE % | 42.5% | 34.3% | 21.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Lumbard & Kellner, LLC | 1.68% | 1.73M | $7.00M |
| 2 | Blackrock Inc. | 0.90% | 924.00K | $3.74M |
| 3 | Geode Capital Management, LLC | 0.42% | 427.86K | $1.73M |
| 4 | Citadel Advisors Llc | 0.14% | 144.72K | $586.11K |
| 5 | Vanguard Capital Management LLC | 0.13% | 135.78K | $549.92K |
| 6 | Northern Trust Corporation | 0.13% | 131.20K | $531.38K |
| 7 | Hillsdale Investment Management Inc. | 0.12% | 124.80K | $505.44K |
| 8 | Vanguard Portfolio Management LLC | 0.12% | 128.29K | $519.59K |
| 9 | Segall Bryant & Hamill, LLC | 0.08% | 81.31K | $329.29K |
| 10 | Vanguard Fiduciary Trust Co | 0.06% | 66.28K | $268.44K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SBC
SBC Medical Group Re-Accelerates Growth as EBITDA Surges 32% in Q2
SBC Medical Group (NASDAQ:SBC) said its growth re-accelerated in the second quarter of 2026 following structural reforms undertaken in 2025, with profit growth exceeding revenue growth as the company expanded management services revenue and…
SBC Medical Group Holdings Inc (SBC) (Q2 2026) Earnings Call Highlights: Profit Growth Outpaces ...
Adjusted EBITDA surges 32% to $20 million as clinic network expands to 287 locations and global initiatives gain momentum.
SBC Medical (SBC) Q2 2026 Earnings Call Transcript
Net income surged 335% as structural reforms boosted margins and clinic expansion.
SBC Medical Group Q2 Growth Re-Accelerates as EBITDA Surges 32%
SBC Medical Group (NASDAQ:SBC) said its growth re-accelerated in the second quarter of 2026 as the company completed structural reforms undertaken in 2025, expanded its clinic network and increased management-services revenue. The medical s…
Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live stream
MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging Growth Conference identifies compan…
SBC Medical to Announce 2Q 2026 Financial Results
IRVINE, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization providing management support across a wide range of healthcare fields,…
SBC — Frequently Asked Questions
What is the current share price of SBC Medical Group Holdings Incorporated (SBC)?
As of 2026-09-07 16:24 PDT, SBC Medical Group Holdings Incorporated (SBC) trades at $4.12 on NasdaqGM. Its 52-week range is $2.87 to $4.99.
What is the market capitalisation of SBC?
SBC Medical Group Holdings Incorporated (SBC) has a market capitalisation of $423.73M on NasdaqGM.
What is the P/E ratio of SBC?
SBC trades at a trailing price-to-earnings (P/E) ratio of 10.30. The industry average P/E is 27.38. Its price-to-book (P/B) ratio is 1.23.
What is the return on equity (ROE) of SBC?
SBC has a return on equity (ROE) of 16.46%. Its return on capital employed (ROCE) is 21.13%.
Is SBC a good stock to buy?
This page provides a data-driven analysis of SBC Medical Group Holdings Incorporated (SBC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.